Chu-Ting Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chu-Ting Chang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Guei‐Jane Wang
National Research Institute of Chinese Medicine, Taipei, 11221, Taiwan
1 shared publication - Shao-Chun Lu
National Taiwan University
1 shared publication - Shwu-Fen Chang
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
1 shared publication - Tzong-Huei Lee
National Taiwan University
1 shared publication - Wei-Jern Tsai
Institute of Life Science, Fu-Jen University, Taipei, 24205, Taiwan.
1 shared publication - Yuh-Chi Kuo
LS212, Laboratory of Molecular Pharmacology, Department of Life Science, Fu-Jen Catholic University, No. 510, Chung-Cheng Road, Hsinchuang 242, New Taipei, Taiwan
1 shared publication
Latest Publications
- Open Access
- 25 March 2011
- Published by Springer Nature in Chinese Medicine
- Vol. 6 (1) , 12
Arctigenin from Arctium lappa inhibits interleukin-2 and interferon gene expression in primary human T lymphocytes
Background: Arctium lappa (Niubang), a Chinese herbal medicine, is used to treat tissue inflammation. This study investigates the effects of arctigenin (AC), isolated from A. lappa, on anti-CD3/CD28 Ab-stimulated cell proliferation and cytokine gene expression in primary human T lymphocytes. Methods: Cell proliferation was determined with enzyme immunoassays and the tritiated thymidine uptake method. Cytokine production and gene expression were analyzed with reverse transcription-polymerase chain reaction. Results: AC inhibited primary human T lymphocytes proliferation activated by anti-CD3/CD28 Ab. Cell viability test indicated that the inhibitory effects of AC on primary human T lymphocyte proliferation were not due to direct cytotoxicity. AC suppressed interleukin-2 (IL-2) and interferon-γ (IFN-γ) production in a concentration-dependent manner. Furthermore, AC decreased the IL-2 and IFN-γ gene expression in primary human T lymphocytes induced by anti-CD3/CD28 Ab. Reporter gene analyses revealed that AC decreased NF-AT-mediated reporter gene expression. Conclusion: AC inhibited T lymphocyte proliferation and decreased the gene expression of IL-2, IFN-γ and NF-AT.
- 25 March 2011
- Published by Springer Nature in Chinese Medicine
- Vol. 6 (1) , 12
Open AccessArctigenin from Arctium lappa inhibits interleukin-2 and interferon gene expression in primary human T lymphocytes
Background: Arctium lappa (Niubang), a Chinese herbal medicine, is used to treat tissue inflammation. This study investigates the effects of arctigenin (AC), isolated from A. lappa, on anti-CD3/CD28 Ab-stimulated cell proliferation and cytokine gene expression in primary human T lymphocytes. Methods: Cell proliferation was determined with enzyme immunoassays and the tritiated thymidine uptake method. Cytokine production and gene expression were analyzed with reverse transcription-polymerase chain reaction. Results: AC inhibited primary human T lymphocytes proliferation activated by anti-CD3/CD28 Ab. Cell viability test indicated that the inhibitory effects of AC on primary human T lymphocyte proliferation were not due to direct cytotoxicity. AC suppressed interleukin-2 (IL-2) and interferon-γ (IFN-γ) production in a concentration-dependent manner. Furthermore, AC decreased the IL-2 and IFN-γ gene expression in primary human T lymphocytes induced by anti-CD3/CD28 Ab. Reporter gene analyses revealed that AC decreased NF-AT-mediated reporter gene expression. Conclusion: AC inhibited T lymphocyte proliferation and decreased the gene expression of IL-2, IFN-γ and NF-AT.